MeiraGTx announces three-year data from Phase 1 AQUAx study

MeiraGTx (MGTX) announced positive three-year data from the completed Phase 1 AQUAx study of AAV-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomia. “Today we are very pleased to be releasing 3-year data from the Phase 1 AQUAx study which includes the full 36-month data from all cohorts,” said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. “The 3-year data shows remarkable maintenance of the unprecedented improvements seen in response to AAV-hAQP1 treatment at 12 months. XQ responses are maintained over 3 years as is unstimulated saliva flow – the objective measure of the therapy’s mechanism of action. The durability we are seeing with AAV-hAQP1 is extraordinary, particularly following the simple one-time treatment. In addition to the durability of the population data over three years, the consistency of responses within individual patients is also encouraging. This three-year durability data is changing the way AAV-hAQP1 treatment is viewed by physicians, as it is now being regarded as a simple one-time treatment that has disease modifying impact on patients with this lifelong, severely debilitating condition that has no other treatments.”